Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 9;139(23):3366–3375. doi: 10.1182/blood.2021011583

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology

Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 1. — Patient disposition. (A) Disposition according to treatment received. (B) Disposition according to transplantation status: patients remaining alive for ≥2 years without relapse in the gilteritinib arm. (C) Disposition by preselected chemotherapy: patients remaining alive for ≥2 years without relapse in the gilteritinib arm. Due to limited follow-up of patients in the SC arm, data related to posttransplant relapse and survival were not available. ITT, intention-to-treat.

Figure 1. — Patient disposition. (A) Disposition according to treatment received. (B) Disposition according to transplantation status: patients remaining alive for ≥2 years without relapse in the gilteritinib arm. (C) Disposition by preselected chemotherapy: patients remaining alive for ≥2 years without relapse in the gilteritinib arm. Due to limited follow-up of patients in the SC arm, data related to posttransplant relapse and survival were not available. ITT, intention-to-treat.